New drug cocktail shows promise against tough head and neck cancers
NCT ID NCT07550972
First seen Apr 28, 2026 · Last updated Jun 14, 2026 · Updated 5 times
Summary
This study tests two drugs, pertuzumab and lenvatinib, given before surgery to people with advanced head and neck cancer that hasn't spread. The goal is to see if this combination can shrink tumors enough to improve surgery results. About 30 adults who haven't had prior treatment for this cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China
Conditions
Explore the condition pages connected to this study.